Shire Offers €428 Million for Movetis To Expand Its GI Drug Portfolio
This article was originally published in The Pink Sheet Daily
Executive Summary
The J&J spin out, which raised more than €97 million in an IPO only eight months ago, would add to Shire's small but fast-growing gastrointestinal therapies franchise.
You may also be interested in...
On A Revenue Roll, Shire Takes Specialist Tactics To “Primary Care” Markets
Shire targets specialist segments of vast primary care populations, with focus on areas of unmet need.
Sofinnova Ventures' New $440M Eighth Fund Exceeds Expectations And Makes Adjustments
The firm wins higher commitments from limited partners, turning its health-care focus to late stage companies and forgoing high-tech investments.
Sofinnova Ventures' New $440M Eighth Fund Exceeds Expectations And Makes Adjustments
The firm wins higher commitments from limited partners, turning its health-care focus to late stage companies and forgoing high-tech investments.